| Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC : From Bedside to Bench and Back | BioDrugs |  | | 2025 | 61 | 1,050 |
|
| Case Report : Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation : a case series and literature review | Frontiers in oncology | | | 2025 | 10 | 408 |
|
| Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review | Journal of thoracic oncology | | | 2024 | 180 | 1,295 |
|
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | | 2024 | 81 | 265 |
|
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | | 2023 | 58 | 174 |
|
| Pleural mesothelioma in the era of immunotherapy | Clinical medicine insights. Oncology | | | 2023 | 70 | 195 |
|
